Literature DB >> 18483817

[Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

K Güttler1, R Sabatowski.   

Abstract

The oral "around-the clock" administration of sustained-release strong opioids has been recommended for the long-term treatment of patients suffering from chronic severe pain. At present a plethora of products are available in Germany. Modern galenics even allow for only once-daily oral application without clinically relevant negative chronobiological interference. This application scheme has been shown to improve compliance and sleep quality, factors that influence treatment outcome. Randomized controlled studies revealed no relevant differences between the different strong opioids with respect to efficacy and tolerability. However, hydromorphone and oxycodone appear to be advantageous over morphine due to a lack of immunosuppression. Hydromorphone has the additional benefit of a lower risk of intoxication by accumulation of active metabolites in patients with decreased renal function. As a result, although morphine has been regarded as the standard for the treatment of chronic severe pain, hydromorphone and oxycodone may be better and safer alternatives for certain patient groups (e.g. older age, multimorbidity, cancer).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483817     DOI: 10.1007/s00482-008-0657-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  70 in total

Review 1.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

2.  Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

Authors:  S H Kollins; C R Rush; P J Pazzaglia; J A Ali
Journal:  Exp Clin Psychopharmacol       Date:  1998-11       Impact factor: 3.157

3.  Long lasting respiratory depression induced by morphine-6-glucuronide?

Authors:  J Hasselström; U Berg; A Löfgren; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 4.  Oxycodone. Pharmacological profile and clinical data in chronic pain management.

Authors:  F Coluzzi; C Mattia
Journal:  Minerva Anestesiol       Date:  2005 Jul-Aug       Impact factor: 3.051

5.  Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.

Authors:  Neil A Hagen; Michael Thirlwell; John Eisenhoffer; Patricia Quigley; Zoltan Harsanyi; Andrew Darke
Journal:  J Pain Symptom Manage       Date:  2005-01       Impact factor: 3.612

Review 6.  Hydromorphone for acute and chronic pain.

Authors:  C Quigley
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  The role of opioids in cancer pain management.

Authors:  Mikhail Fukshansky; Madhuri Are; Allen W Burton
Journal:  Pain Pract       Date:  2005-03       Impact factor: 3.183

Review 8.  Opioid dependence and addiction during opioid treatment of chronic pain.

Authors:  Jane C Ballantyne; Steven K LaForge
Journal:  Pain       Date:  2007-05-04       Impact factor: 6.961

9.  Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers.

Authors:  M P Yeager; T A Colacchio; C T Yu; L Hildebrandt; A L Howell; J Weiss; P M Guyre
Journal:  Anesthesiology       Date:  1995-09       Impact factor: 7.892

10.  Morphine pellet-induced immunomodulation in mice: temporal relationships.

Authors:  H U Bryant; E W Bernton; J W Holaday
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

View more
  2 in total

1.  Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum.

Authors:  Uwe Wollina
Journal:  J Dermatol Case Rep       Date:  2013-09-30

2.  The opioid oxycodone use-dependently inhibits the cardiac sodium channel NaV 1.5.

Authors:  Jannis E Meents; Krisztina Juhasz; Sonja Stölzle-Feix; Vera Peuckmann-Post; Roman Rolke; Angelika Lampert
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.